The new Federal Act on Data Protection (nFADP) Guidance for clinical trials

Abstract

On 1st of September 2023, the new Federal Act on Data Protection (nFADP) came into force. The revision improves the processing of personal data and grants Swiss citizens new rights. The nFADP applies to all Swiss-based and international companies that provide goods or services to Swiss citizens and to organizations that process sensitive data, such as medical records and genetic material. This short guide shall help you to understand whether the nFADP is relevant for your clinical research project and what the most important changes are as compared to the old FDAP.

Imprint

Recommended form of citation

Regulatory Affairs Platform of the Swiss Clinical Trial Organisation (SCTO) (2023): The new Federal Act on Data Protection (nFADP) Guidance for clinical trials. Edited by the SCTO. doi: 10.54920/SCTO.2023.02

Copyright

This publication is licensed under CC BY-NC 4.0. The content of this publication may be shared and adapted as long as you follow the terms of the license. To view a copy of the license, visit http://creativecommons.org/licenses/by-nc/4.0/. Please attribute this resource to “Swiss Clinical Trial Organisation (Regulatory Affairs Platform)” and link to the following website: www.sctoplatforms.ch. 

Contact

To give feedback on this publication or obtain further information, you can contact platforms@scto.ch